158 related articles for article (PubMed ID: 36029713)
1. Colon cancer CT staging according to mismatch repair status: Comparison and suggestion of imaging features for high-risk colon cancer.
Hong EK; Chalabi M; Landolfi F; Castagnoli F; Park SJ; Sikorska K; Aalbers A; van den Berg J; van Leerdam M; Lee JM; Beets-Tan R
Eur J Cancer; 2022 Oct; 174():165-175. PubMed ID: 36029713
[TBL] [Abstract][Full Text] [Related]
2. The impact of mismatch repair status and systemic inflammatory markers on radiological staging in colon cancer.
Platt JR; Ansett J; Seligmann JF; West NP; Tolan DJM
Br J Radiol; 2023 Oct; 96(1150):20230098. PubMed ID: 37493144
[TBL] [Abstract][Full Text] [Related]
3. Preoperative contrast-enhanced CT imaging and clinicopathological characteristics analysis of mismatch repair-deficient colorectal cancer.
Chen S; Du W; Cao Y; Kong J; Wang X; Wang Y; Lu Y; Li X
Cancer Imaging; 2023 Oct; 23(1):97. PubMed ID: 37828626
[TBL] [Abstract][Full Text] [Related]
4. Intertumoral Heterogeneity of CD3
Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
[TBL] [Abstract][Full Text] [Related]
5. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
[TBL] [Abstract][Full Text] [Related]
6. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
7. Preoperative Strategies for Locally Advanced Colon Cancer.
Nair KG; Kamath SD; Chowattukunnel N; Krishnamurthi SS
Curr Treat Options Oncol; 2024 Mar; 25(3):376-388. PubMed ID: 38349502
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Chalabi M; Fanchi LF; Dijkstra KK; Van den Berg JG; Aalbers AG; Sikorska K; Lopez-Yurda M; Grootscholten C; Beets GL; Snaebjornsson P; Maas M; Mertz M; Veninga V; Bounova G; Broeks A; Beets-Tan RG; de Wijkerslooth TR; van Lent AU; Marsman HA; Nuijten E; Kok NF; Kuiper M; Verbeek WH; Kok M; Van Leerdam ME; Schumacher TN; Voest EE; Haanen JB
Nat Med; 2020 Apr; 26(4):566-576. PubMed ID: 32251400
[TBL] [Abstract][Full Text] [Related]
9. The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency.
Yunlong W; Tongtong L; Hua Z
Cancer Med; 2023 Feb; 12(3):2440-2452. PubMed ID: 35904113
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
11. Different surgical outcome and follow-up status between dMMR and pMMR colorectal cancer patients who fulfilled with Amsterdam-II criteria.
Sun CY; Chiang JM; Chen TC; Hung HY; You JF
World J Surg Oncol; 2020 Aug; 18(1):195. PubMed ID: 32767993
[TBL] [Abstract][Full Text] [Related]
12. Computed Tomography Features of Gastric Cancer Patients With DNA Mismatch Repair Deficiency.
Cao Q; Lai SY; Xu N; Lu Y; Chen S; Zhang XS; Li X
Front Oncol; 2021; 11():619439. PubMed ID: 33816249
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.
Rohr UP; Herrmann P; Ilm K; Zhang H; Lohmann S; Reiser A; Muranyi A; Smith J; Burock S; Osterland M; Leith K; Singh S; Brunhoeber P; Bowermaster R; Tie J; Christie M; Wong HL; Waring P; Shanmugam K; Gibbs P; Stein U
Ann Oncol; 2017 Aug; 28(8):1869-1875. PubMed ID: 28460000
[TBL] [Abstract][Full Text] [Related]
15. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
[TBL] [Abstract][Full Text] [Related]
16. Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.
Rasola C; Laurent-Puig P; André T; Falcoz A; Lepage C; Aparicio T; Bouché O; Lievre A; Mineur L; Bennouna J; Louvet C; Bachet JB; Borg C; Vernerey D; Lonardi S; Taieb J
Eur J Cancer; 2023 Nov; 194():113321. PubMed ID: 37797388
[TBL] [Abstract][Full Text] [Related]
17. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J
PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813
[TBL] [Abstract][Full Text] [Related]
18. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
[TBL] [Abstract][Full Text] [Related]
19. Impact of mismatch repair deficiency on tumour regression grade after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma.
Heran M; Renaud F; Louvet C; Piessen G; Voron T; Lefèvre M; Dubreuil O; André T; Svrcek M; Cohen R
Dig Liver Dis; 2023 Feb; 55(2):276-282. PubMed ID: 35780065
[TBL] [Abstract][Full Text] [Related]
20. Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status.
Jenniskens JCA; Offermans K; Simons CCJM; Samarska I; Fazzi GE; van der Meer JRM; Smits KM; Schouten LJ; Weijenberg MP; Grabsch HI; van den Brandt PA
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2723-2742. PubMed ID: 35546360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
